New hope for lymphoma patients: glofitamab studied in Real-World setting
NCT ID NCT07200375
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of their normal cancer care to see how long they live without the cancer getting worse and how many achieve complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab
- What this could lead to
- If successful, this study could confirm that glofitamab is an effective second-line treatment for relapsed or refractory DLBCL in real-world Chinese patients.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. Glofitamab can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences.
RECRUITINGLangfang, Hebei, 065001, China
-
Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center
RECRUITINGTianjin, Tianjin Municipality, 301636, China
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, 510080, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, 150081, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, 450008, China
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
-
Peking University Third Hospital
RECRUITINGBeijing, 100191, China
-
Queen Mary Hospital
RECRUITINGHong Kong, Hong Kong
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, 200025, China
-
Shandong Cancer Hospital
RECRUITINGJinan, 250117, China
-
Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, 200233, China
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, 325035, China
-
The First Affiliated Hospital of Xian Jiao Tong University
RECRUITINGXi'an, 710061, China
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, China
-
Tianjin Cancer Hospital
RECRUITINGTianjin, 300060, China
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITINGWuhan, 430030, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, 610041, China
-
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
RECRUITINGWuhan, 430022, China
-
Yantai Yu Huangding Hospital
RECRUITINGYantai, 264099, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers